End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Pipeline Review, H2 2017’, provides an overview of the End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)

The report reviews pipeline therapeutics for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) therapeutics and enlists all their major and minor projects

The report assesses End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

CTI BioPharma Corp

Merck & Co Inc

Novartis AG

Prolong Pharmaceuticals LLC

VESSL Therapeutics Ltd

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 4

Introduction 5

Global Markets Direct Report Coverage 5

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Overview 6

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Development 7

Pipeline Overview 7

Pipeline by Companies 8

Products under Development by Companies 9

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Therapeutics Assessment 10

Assessment by Target 10

Assessment by Mechanism of Action 12

Assessment by Route of Administration 14

Assessment by Molecule Type 16

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Companies Involved in Therapeutics Development 18

CTI BioPharma Corp 18

Merck & Co Inc 18

Novartis AG 19

Prolong Pharmaceuticals LLC 19

VESSL Therapeutics Ltd 20

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Drug Profiles 21

calcium succinate - Drug Profile 21

Product Description 21

Mechanism Of Action 21

R&D Progress 21

Cell Therapy for Peripheral Arterial Disease and End-Stage Kidney Disease - Drug Profile 22

Product Description 22

Mechanism Of Action 22

R&D Progress 22

MK-3866 - Drug Profile 23

Product Description 23

Mechanism Of Action 23

R&D Progress 23

pacritinib - Drug Profile 24

Product Description 24

Mechanism Of Action 24

R&D Progress 24

Recombinant Plasma Gelsolin Replacement for Renal Disease - Drug Profile 38

Product Description 38

Mechanism Of Action 38

R&D Progress 38

Sanguinate - Drug Profile 39

Product Description 39

Mechanism Of Action 39

R&D Progress 39

tesidolumab - Drug Profile 42

Product Description 42

Mechanism Of Action 42

R&D Progress 42

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Dormant Projects 44

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) - Discontinued Products 45

Appendix 46

Methodology 46

Coverage 46

Secondary Research 46

Primary Research 46

Expert Panel Validation 46

Contact Us 46

Disclaimer 47

List of Tables

List of Tables

Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Products under Development by Companies, H2 2017 9

Number of Products by Stage and Target, H2 2017 11

Number of Products by Stage and Mechanism of Action, H2 2017 13

Number of Products by Stage and Route of Administration, H2 2017 15

Number of Products by Stage and Molecule Type, H2 2017 17

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Pipeline by CTI BioPharma Corp, H2 2017 18

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Pipeline by Merck & Co Inc, H2 2017 19

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Pipeline by Novartis AG, H2 2017 19

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Pipeline by Prolong Pharmaceuticals LLC, H2 2017 20

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Pipeline by VESSL Therapeutics Ltd, H2 2017 20

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Dormant Projects, H2 2017 44

End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Discontinued Products, H2 2017 45

List of Figures

List of Figures

Number of Products under Development for End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), H2 2017 7

Number of Products under Development by Companies, H2 2017 8

Number of Products by Targets, H2 2017 10

Number of Products by Stage and Targets, H2 2017 10

Number of Products by Mechanism of Actions, H2 2017 12

Number of Products by Stage and Mechanism of Actions, H2 2017 12

Number of Products by Routes of Administration, H2 2017 14

Number of Products by Stage and Top 10 Routes of Administration, H2 2017 14

Number of Products by Molecule Types, H2 2017 16

Number of Products by Stage and Molecule Types, H2 2017 16

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports